Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Baidu, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation Details - The investigation is prompted by allegations that Baidu may have engaged in securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Market Reaction - On November 26, 2025, it was reported that the Pentagon concluded Baidu should be added to a list of companies that assist the Chinese military [3]. - Following this news, Baidu's American Depositary Receipt (ADR) price decreased by $1.54, or 1.31%, closing at $116.34 per ADR on the same day [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4]. - The firm has successfully recovered numerous multimillion-dollar damages awards for class members [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Waldencast plc and its officers or directors [1]. Financial Performance - On November 24, 2025, Waldencast reported its financial results for Q2 2025, revising its full-year 2025 net revenue outlook to be broadly in line with 2024, with an adjusted EBITDA margin expected in the high single digits [3]. - Previously, Waldencast had projected mid-teens net revenue growth and an adjusted EBITDA margin in the mid-to-high teens [3]. - The company reported a net loss of $185.2 million for the first half of 2025, primarily due to impairment charges of $132.1 million and $20 million related to its Obagi Medical and Milk Makeup brands [3]. Market Reaction - Following the financial update, Waldencast's Class A ordinary share price decreased by $0.20, or 6.49%, closing at $2.88 per share on November 24, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust (REIT) focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met once inventory was available [5]. - Contrary to these assurances, Inspire failed to adequately prepare clinicians and payors, leading to delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and had a poor customer experience leading to higher withdrawal rates and lower conversion rates [4]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60 per share, over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, more than 54%, from $153.53 to $70.05 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [3]. Investor Information - Investors are encouraged to seek additional information regarding their legal options and can submit their information to the law firm representing the class action [2][7]. - The law firm operates on a contingency fee basis, meaning there are no upfront costs for shareholders [7]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and has a strong track record, including recovering over $900 million from Tesla's Board of Directors [8].

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Bgin Blockchain Limited regarding potential violations of federal securities laws affecting investors [1] Company Summary - Bgin Blockchain Limited is listed on NASDAQ under the ticker symbol BGIN [1] - The investigation is aimed at assessing the company's compliance with federal securities regulations [1] Investor Impact - The law firm is reaching out to investors who may have incurred losses related to their investments in Bgin Blockchain Limited [1]

Core Viewpoint - An investigation has been announced regarding New Era Energy & Digital, Inc. for potential violations of federal securities laws, indicating possible legal challenges for the company and its investors [1]. Company Summary - New Era Energy & Digital, Inc. is under scrutiny for possible legal issues that may affect its stock performance and investor confidence [1]. - Investors who have experienced losses in New Era Energy & Digital, Inc. are encouraged to contact legal representatives to explore options for recovering their losses [1].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Graphic Packaging Holding Company (“Graphic Packaging” or the “Company”) (NYSE: GPK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Graphic Packaging and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining ...

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ardent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On November 12, ...

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Lakeland Industries, Inc. (“Lakeland” or the “Company”) (NASDAQ: LAKE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Lakeland and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...